BioSpace News Archive

Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced two oral presentations at the 62nd ASH Annual Meeting and Exposition in December.

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended September 30, 2020.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced the filing of its third quarter 2020 Form 10-Q for the period ended September 30, 2020.

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2020 and recent business highlights.

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its full financial and operational results for the quarter ending September 30, 2020.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced its financial results for the third quarter ended September 30, 2020. “This quarter we drove strong performance through the conti

-- Updated Phase 2 results for hepcidin mimetic PTG-300 in polycythemia vera accepted for oral presentation at the ASH Annual Meeting in December 2020 -- -- PTG-300 received European Medicine Agency (EMA) Orphan Drug Designation for the treatment of polycythemia vera -- -- Company is advancing additional oral IL-23 receptor antagonists into clinical development in collaboration with Janssen --

XPhyto Therapeutics Corp., a next-generation bioscience accelerator, is pleased to announce the appointment of Mr. Per S. Thoresen to the Company’s board of directors effective immediately.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company’s shares of common stock. “This share repurchase program reflects our confidence in the long-term outlook for the Company, including our ability to generat

- Offered with 100 percent sensitivity[i] with samples with a PCR Cycle Threshold (CT) of less than 34, Ortho’s test may be better able to identify individuals with COVID-19 who are infectious compared to PCR - Ortho’s new SARS-CoV-2 antigen test is the latest addition to the company’s COVID-19 solutions, which include two COVID-19 antibody tests, Total and IgG--both of which have CE Mark and FDA Emergency Use Authorization